Physician profile
Andrew Daugherty
NPI 1538583703
$5,239.87
in general payments reported to CMS, 2019-2025
27 companies · $2,228 in 2025
The $2,228 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2021: $89.95 · 2022: $328 · 2023: $551 · 2024: $1,921 · 2025: $2,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,488 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,488.46 |
| Education | $211.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.84 | 2022-2025 | Rinvoq, Botox |
| Sun Pharmaceutical Industries INC. | $921.49 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $645.07 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $396.66 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $349.29 | 2023-2024 | Vtama |
| Pfizer INC. | $282.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $250.94 | 2022-2025 | |
| Ucb, INC. | $212.13 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $164.92 | 2023-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $121.86 | 2019 | |
| Biofrontera INC. | $118.35 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $117.29 | 2022-2025 | Dupixent, Libtayo |
| Organon LLC | $111.13 | 2025 | Vtama, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.48 | 2023-2024 | Spevigo, Cyltezo |
| Incyte Corporation | $73.25 | 2022-2024 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $61.92 | 2023-2025 | Poteligeo |
| Leo Pharma INC. | $59.50 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $47.63 | 2022-2024 | Otezla |
| Botanix Sb INC | $39.15 | 2025 | Sofdra |
| Lilly USA, LLC | $39.05 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Allergan, INC. | $37.68 | 2022 | |
| Arcutis Biotherapeutics, INC. | $35.22 | 2024 | Zoryve |
| Cipher Pharmaceuticals US LLC | $22.36 | 2025 | Natroba, Spinosad |
| Lnhc, INC | $21.87 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $14.47 | 2025 | |
| Strata Skin Sciences, INC. | $14.41 | 2025 | Xtrac |
| Galderma Laboratories, L.P. | $13.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.